Cargando…

Cardiac arrhythmia induced by genetic silencing of “funny” (f) channels is rescued by GIRK4 inactivation

The mechanisms underlying cardiac automaticity are still incompletely understood and controversial. Here we report the complete conditional and time-controlled silencing of the "funny" current (I(f)) by expression of a dominant-negative, non-conductive HCN4-channel subunit (hHCN4-AYA). Hea...

Descripción completa

Detalles Bibliográficos
Autores principales: Mesirca, Pietro, Alig, Jacqueline, Torrente, Angelo G., Müller, Jana Christina, Marger, Laurine, Rollin, Anne, Marquilly, Claire, Vincent, Anne, Dubel, Stefan, Bidaud, Isabelle, Fernandez, Anne, Seniuk, Anika, Engeland, Birgit, Singh, Jasmin, Miquerol, Lucile, Ehmke, Heimo, Eschenhagen, Thomas, Nargeot, Joel, Wickman, Kevin, Isbrandt, Dirk, Mangoni, Matteo E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4207211/
https://www.ncbi.nlm.nih.gov/pubmed/25144323
http://dx.doi.org/10.1038/ncomms5664
Descripción
Sumario:The mechanisms underlying cardiac automaticity are still incompletely understood and controversial. Here we report the complete conditional and time-controlled silencing of the "funny" current (I(f)) by expression of a dominant-negative, non-conductive HCN4-channel subunit (hHCN4-AYA). Heart-specific I(f) silencing caused altered [Ca(2+)](i) release and Ca(2+) handling in the sinoatrial node, impaired pacemaker activity, and symptoms reminiscent of severe human disease of pacemaking. The effects of I(f) silencing critically depended on the activity of the autonomic nervous system. We were able to rescue the failure of impulse generation and conduction by additional genetic deletion of cardiac muscarinic G-protein-activated (GIRK4) channels in I(f)-deficient mice without impairing heartbeat regulation. Our study establishes the role of f-channels in cardiac automaticity and indicates that arrhythmia related to HCN loss-of-function may be managed by pharmacological or genetic inhibition of GIRK4 channels, thus offering a new therapeutic strategy for the treatment of heart rhythm diseases.